Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MAVENCLAD | EMD Serono | N-022561 RX | 2019-03-29 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
cladribine | ANDA | 2025-01-23 |
mavenclad | New Drug Application | 2024-05-21 |
Code | Description |
---|---|
J9065 | Injection, cladribine, per 1 mg |
Drug common name | Cladribine |
INN | cladribine |
Description | Cladribine is 2'-Deoxyadenosine in which the hydrogen at position 2 on the purine ring has been substituted by chlorine. It inhibits the synthesis and repair of DNA, particularly in lymphocytes and monocytes, and is used as an antimetabolite antineoplastic drug for the treatment of lymphoid malignancies including hairy-cell leukaemia and chronic lymphocytic leukaemia. It has a role as an antineoplastic agent and an immunosuppressive agent. It is a purine 2'-deoxyribonucleoside and an organochlorine compound. |
Classification | Small molecule |
Drug class | ribofuranil derivatives (pyrazofurin type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1 |
PDB | — |
CAS-ID | 4291-63-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1619 |
ChEBI ID | 567361 |
PubChem CID | 20279 |
DrugBank | DB00242 |
UNII ID | 47M74X9YT5 (ChemIDplus, GSRS) |